Skip to main content
Delfa

← Trials/Trial dossier/NCT00750529

CompletedPhase 1

Alzheimer and Sleep

Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.

Asset

Galantamine

Listed sites

2

Recruiting sites

-

Enrollment

15

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age ≥65

Primary endpoint

•Comparison of the percentage of paradoxical sleep recorded

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDCHU-0038
NCT IDNCT00750529

Timeline

Milestones

Study first posted2008-09-10estimated
Study start2008-11 (month precision)
Primary completion2013-09actual (month precision)
Study completion2013-09actual (month precision)
Last update posted2014-07-08estimated

Assets

Drug assets

Galantamine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•65 and over years old
•Patients suffering from Alzheimer disease
•Patient living with someone at home
•Written consent given

Exclusion criteria

•Galantamine or Donepezil hypersensibility
•Patient living alone and in a medicalized structure
•Concomitant medication
•Chronical diseases

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Behavior / neuropsychiatric

2 endpoints
Primary/protocol endpoint

Comparison of the percentage of paradoxical sleep recorded with polysomonography in 65 years old patients with administration of Galantamine or Donépézil

Time frame:administration of galantamine or donépézil

threshold achievement, improvement

Secondary/protocol endpoint

Describe the iatrogenic modifications of rhythm and architecture of sleep. describe the iatrogenic modifications of rythm and architecture of sleep

Time frame:during the iatrogenic modifications

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.